FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319655851> ?p ?o ?g. }

• W4319655851 endingPage "519" @default.
• W4319655851 startingPage "519" @default.
• W4319655851 abstract "The ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.To explore the optimal therapy for patients with intermediate-risk AML after first complete remission.This investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLA)-matched sibling or unrelated donor. A detailed statistical analysis plan was written and finalized on July 7, 2020. Data were exported for analysis on April 13, 2021.Patients were randomized 1:1 to receive allogeneic hematopoietic cell transplantation (HCT) or high-dose cytarabine for consolidation and salvage HCT only in case of relapse. Strata for randomization included age (18-40 vs 41-60 years), NPM1 and CEBPA variation status, and donor type (unrelated vs related).End points included overall-survival as the primary outcome and disease-free survival, cumulative incidence of relapse, treatment-related mortality, and quality of life measured according to the Medical Outcomes Study 36-Item Short-Form Health Survey as secondary outcomes.A total of 143 patients (mean [SD] age, 48.2 [9.8] years; 81 [57%] male) with AML who fulfilled the eligibility criteria were randomized. In the intention-to-treat analysis, the probability of survival at 2 years was 74% (95% CI, 62%-83%) after primary allogeneic HCT and 84% (95% CI, 73%-92%) after consolidation chemotherapy (P = .22). Disease-free survival after HCT at 2 years was 69% (95% CI, 57%-80%) compared with 40% (95% CI, 28%-53%) after consolidation chemotherapy (P = .001). Allogeneic HCT during the first CR was associated with a cumulative incidence of relapse at 2 years of 20% (95% CI, 13%-31%) compared with 58% (95% CI, 47%-71%; P < .001). Nonrelapse mortality at 2 years after primary allogeneic HCT was 9% (95% CI, 5%-19%) and 2% (95% CI, 0%-11%) after consolidation chemotherapy (P = .005). Similar outcomes were observed when analyses were confined to the 96 patients at intermediate risk according to the European Leukemia Network classification. Most importantly, all 41 patients relapsing after consolidation chemotherapy (36 hematologic, 4 molecular, and 1 extramedullary) proceeded to allogeneic HCT. No significant differences in health-related quality of life measures were observed between groups.Primary allogeneic HCT during first CR was not associated with superior overall survival compared with consolidation chemotherapy in patients 60 years or younger with intermediate-risk AML during the first CR and an available donor.ClinicalTrials.gov Identifier: NCT01246752." @default.
• W4319655851 created "2023-02-10" @default.
• W4319655851 creator A5004741011 @default.
• W4319655851 creator A5006122560 @default.
• W4319655851 creator A5006288618 @default.
• W4319655851 creator A5007449495 @default.
• W4319655851 creator A5010300269 @default.
• W4319655851 creator A5012020159 @default.
• W4319655851 creator A5017002895 @default.
• W4319655851 creator A5020116063 @default.
• W4319655851 creator A5025105470 @default.
• W4319655851 creator A5026359397 @default.
• W4319655851 creator A5026849709 @default.
• W4319655851 creator A5037944783 @default.
• W4319655851 creator A5039007673 @default.
• W4319655851 creator A5039142430 @default.
• W4319655851 creator A5039235274 @default.
• W4319655851 creator A5042951988 @default.
• W4319655851 creator A5047829491 @default.
• W4319655851 creator A5052619425 @default.
• W4319655851 creator A5054393582 @default.
• W4319655851 creator A5061229750 @default.
• W4319655851 creator A5062937497 @default.
• W4319655851 creator A5066994665 @default.
• W4319655851 creator A5071523133 @default.
• W4319655851 creator A5073313603 @default.
• W4319655851 creator A5079124367 @default.
• W4319655851 creator A5084826011 @default.
• W4319655851 creator A5086016311 @default.
• W4319655851 creator A5087237103 @default.
• W4319655851 creator A5090795046 @default.
• W4319655851 date "2023-04-01" @default.
• W4319655851 modified "2023-10-16" @default.
• W4319655851 title "Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia" @default.
• W4319655851 cites W1978164777 @default.
• W4319655851 cites W2007302457 @default.
• W4319655851 cites W2014357452 @default.
• W4319655851 cites W2017000328 @default.
• W4319655851 cites W2066915026 @default.
• W4319655851 cites W2074425311 @default.
• W4319655851 cites W2080129735 @default.
• W4319655851 cites W2090352304 @default.
• W4319655851 cites W2097192169 @default.
• W4319655851 cites W2118693086 @default.
• W4319655851 cites W2141034604 @default.
• W4319655851 cites W2144395887 @default.
• W4319655851 cites W2159507916 @default.
• W4319655851 cites W2172151487 @default.
• W4319655851 cites W2237124828 @default.
• W4319655851 cites W2296458069 @default.
• W4319655851 cites W2559537906 @default.
• W4319655851 cites W2590030902 @default.
• W4319655851 cites W2751152093 @default.
• W4319655851 cites W2783450169 @default.
• W4319655851 cites W2794188069 @default.
• W4319655851 cites W2889920057 @default.
• W4319655851 cites W2996657019 @default.
• W4319655851 cites W3001829780 @default.
• W4319655851 cites W3011104356 @default.
• W4319655851 cites W3042846071 @default.
• W4319655851 cites W3047808971 @default.
• W4319655851 cites W4245960213 @default.
• W4319655851 cites W4376595466 @default.
• W4319655851 doi "https://doi.org/10.1001/jamaoncol.2022.7605" @default.
• W4319655851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36757706" @default.
• W4319655851 hasPublicationYear "2023" @default.
• W4319655851 type Work @default.
• W4319655851 citedByCount "3" @default.
• W4319655851 countsByYear W43196558512023 @default.
• W4319655851 crossrefType "journal-article" @default.
• W4319655851 hasAuthorship W4319655851A5004741011 @default.
• W4319655851 hasAuthorship W4319655851A5006122560 @default.
• W4319655851 hasAuthorship W4319655851A5006288618 @default.
• W4319655851 hasAuthorship W4319655851A5007449495 @default.
• W4319655851 hasAuthorship W4319655851A5010300269 @default.
• W4319655851 hasAuthorship W4319655851A5012020159 @default.
• W4319655851 hasAuthorship W4319655851A5017002895 @default.
• W4319655851 hasAuthorship W4319655851A5020116063 @default.
• W4319655851 hasAuthorship W4319655851A5025105470 @default.
• W4319655851 hasAuthorship W4319655851A5026359397 @default.
• W4319655851 hasAuthorship W4319655851A5026849709 @default.
• W4319655851 hasAuthorship W4319655851A5037944783 @default.
• W4319655851 hasAuthorship W4319655851A5039007673 @default.
• W4319655851 hasAuthorship W4319655851A5039142430 @default.
• W4319655851 hasAuthorship W4319655851A5039235274 @default.
• W4319655851 hasAuthorship W4319655851A5042951988 @default.
• W4319655851 hasAuthorship W4319655851A5047829491 @default.
• W4319655851 hasAuthorship W4319655851A5052619425 @default.
• W4319655851 hasAuthorship W4319655851A5054393582 @default.
• W4319655851 hasAuthorship W4319655851A5061229750 @default.
• W4319655851 hasAuthorship W4319655851A5062937497 @default.
• W4319655851 hasAuthorship W4319655851A5066994665 @default.
• W4319655851 hasAuthorship W4319655851A5071523133 @default.
• W4319655851 hasAuthorship W4319655851A5073313603 @default.
• W4319655851 hasAuthorship W4319655851A5079124367 @default.
• W4319655851 hasAuthorship W4319655851A5084826011 @default.
• W4319655851 hasAuthorship W4319655851A5086016311 @default.
• W4319655851 hasAuthorship W4319655851A5087237103 @default.

• next